Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2023

Open Access 16-10-2023 | Huntington's Disease | Case report

Memantine administration prevented chorea movement in Huntington’s disease: a case report

Authors: Kazumasa Saigoh, Makito Hirano, Yoshiyuki Mitsui, Itsuki Oda, Atsuko Ikegawa, Makoto Samukawa, Keisuke Yoshikawa, Yuko Yamagishi, Susumu Kusunoki, Yoshitaka Nagai

Published in: Journal of Medical Case Reports | Issue 1/2023

Login to get access

Abstract

Background

Huntington’s disease is an autosomal dominant inherited disorder characterized by personality changes (such as irritability and restlessness) and psychotic symptoms (such as hallucinations and delusions). When the personality changes become noticeable, involuntary movements (chorea) also develop. The disease is caused by the CAG repeat expansion in the coding region of the HTT gene, and the diagnosis is based on the presence of this expansion. However, there is currently no effective treatment for the progression of Huntington’s disease and its involuntary motor symptoms. Herein, we present a case in which memantine was effective in treating the chorea movements of Huntington’s disease.

Case presentation

A 75-year-old Japanese woman presented to the hospital with involuntary movements of Huntington’s disease that began when she was 73 years old. In a cerebral blood flow test (N-isopropyl-p-iodoamphetamine–single-photon emission computed tomography), decreased blood flow was observed in the precuneus (anterior wedge) and posterior cingulate gyrus. Usually, such areas of decreased blood flow are observed in patients with Alzheimer’s-type dementia. So, we administered memantine for Alzheimer’s-type dementia, and this treatment suppressed the involuntary movements of Huntington’s disease, and the symptoms progressed slowly for 7 years after the onset of senility. In contrast, her brother died of complications of pneumonia during the course of Huntington’s disease.

Conclusions

We recorded changes in parameters such as the results of the N-isopropyl-p-iodoamphetamine–single-photon emission computed tomography and gait videos over 7 years. Treatment with memantine prevented the chorea movement and the progression of Huntington’s disease. We believe this record will provide clinicians with valuable information in diagnosing and treating Huntington’s disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:204–16.CrossRefPubMed Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:204–16.CrossRefPubMed
2.
go back to reference Liu D, Long JD, Zhang Y, Raymond LA, Marder K, Rosser A, PREDICT-HD Investigators and coordinators of the Huntington study group, et al. Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. J Neurol. 2015;262:2691–8.CrossRefPubMedPubMedCentral Liu D, Long JD, Zhang Y, Raymond LA, Marder K, Rosser A, PREDICT-HD Investigators and coordinators of the Huntington study group, et al. Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. J Neurol. 2015;262:2691–8.CrossRefPubMedPubMedCentral
3.
go back to reference Samukawa M, Hirano M, Saigoh K, Kawai S, Hamada Y, Takahashi D, et al. PSP-phenotype in SCA8: case report and systemic review. Cerebellum. 2019;18:76–84.CrossRefPubMed Samukawa M, Hirano M, Saigoh K, Kawai S, Hamada Y, Takahashi D, et al. PSP-phenotype in SCA8: case report and systemic review. Cerebellum. 2019;18:76–84.CrossRefPubMed
4.
go back to reference Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J. Executive dysfunction in early stages of Huntington’s disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci. 2005;239:11–9.CrossRefPubMed Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J. Executive dysfunction in early stages of Huntington’s disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci. 2005;239:11–9.CrossRefPubMed
5.
go back to reference Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.CrossRefPubMed Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.CrossRefPubMed
6.
go back to reference Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.CrossRef Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.CrossRef
7.
go back to reference Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83–98.CrossRefPubMed Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83–98.CrossRefPubMed
8.
go back to reference Johanssen T, Suphantarida N, Donnelly PS, Liu XM, Petrou S, Hill AF, et al. PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning. Neurobiol Dis. 2015;81:176–85.CrossRefPubMed Johanssen T, Suphantarida N, Donnelly PS, Liu XM, Petrou S, Hill AF, et al. PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning. Neurobiol Dis. 2015;81:176–85.CrossRefPubMed
9.
go back to reference Cankurtaran ES, Ozalp E, Soygur H, Cakir A. Clinical experience with risperidone and memantine in the treatment of Huntington’s disease. J Natl Med Assoc. 2006;98:1353–5.PubMedPubMedCentral Cankurtaran ES, Ozalp E, Soygur H, Cakir A. Clinical experience with risperidone and memantine in the treatment of Huntington’s disease. J Natl Med Assoc. 2006;98:1353–5.PubMedPubMedCentral
10.
go back to reference Corey-Bloom J, Goldstein J. Study of memantine to treat Huntington’s Disease. ClinicalTrials.gov database Identifier: NCT00652457, 2008. Corey-Bloom J, Goldstein J. Study of memantine to treat Huntington’s Disease. ClinicalTrials.gov database Identifier: NCT00652457, 2008.
11.
go back to reference Leavitt B, Huntington Study Group. A trial of memantine as smptomatic treatment for early Huntington Disease (MITIGATE-HD). ClinicalTrials.gov database Identifier: NCT01458470, 2011. Leavitt B, Huntington Study Group. A trial of memantine as smptomatic treatment for early Huntington Disease (MITIGATE-HD). ClinicalTrials.gov database Identifier: NCT01458470, 2011.
12.
go back to reference Elkurd MT, Bahroo LB, Pahwa R. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients. Neurodegener Dis Manag. 2018;8:73–80.CrossRefPubMed Elkurd MT, Bahroo LB, Pahwa R. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients. Neurodegener Dis Manag. 2018;8:73–80.CrossRefPubMed
13.
go back to reference Aguilar L, Lorenzo C, Fernández-Ovejero R, Roncero C, Montejo AL. Tardive dyskinesia after aripiprazole treatment that improved with tetrabenazine, clozapine, and botulinum toxin. Front Pharmacol. 2019;10:281.CrossRefPubMedPubMedCentral Aguilar L, Lorenzo C, Fernández-Ovejero R, Roncero C, Montejo AL. Tardive dyskinesia after aripiprazole treatment that improved with tetrabenazine, clozapine, and botulinum toxin. Front Pharmacol. 2019;10:281.CrossRefPubMedPubMedCentral
14.
go back to reference Cummings MA, Proctor GJ, Stahl SM. Deuterium tetrabenazine for tardive dyskinesia. Clin Schizophr Relat Psychoses. 2018;11:214–20.CrossRefPubMed Cummings MA, Proctor GJ, Stahl SM. Deuterium tetrabenazine for tardive dyskinesia. Clin Schizophr Relat Psychoses. 2018;11:214–20.CrossRefPubMed
16.
17.
go back to reference Dau A, Gladding CM, Sepers MD, Raymond LA. Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice. Neurobiol Dis. 2014;62:533–42.CrossRefPubMed Dau A, Gladding CM, Sepers MD, Raymond LA. Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice. Neurobiol Dis. 2014;62:533–42.CrossRefPubMed
18.
go back to reference Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron. 2010;65:178–90.CrossRefPubMed Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron. 2010;65:178–90.CrossRefPubMed
Metadata
Title
Memantine administration prevented chorea movement in Huntington’s disease: a case report
Authors
Kazumasa Saigoh
Makito Hirano
Yoshiyuki Mitsui
Itsuki Oda
Atsuko Ikegawa
Makoto Samukawa
Keisuke Yoshikawa
Yuko Yamagishi
Susumu Kusunoki
Yoshitaka Nagai
Publication date
16-10-2023
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2023
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-023-04161-z

Other articles of this Issue 1/2023

Journal of Medical Case Reports 1/2023 Go to the issue